Effects of anti-inflammatory biflavonoid, ginkgetin, on chronic skin inflammation

Biological and Pharmaceutical Bulletin

Volumn 29, Issue 5, 2006, Pages 1046-1049

  Lim, Hyun ^a   Son, Kun Ho ^b   Chang, Hyeun Wook ^c   Kang, Sam Sik ^d   Kim, Hyun Pyo ^a  

^a Kangwon National University   (South Korea)

^b Andong National University   (South Korea)

^c Yeungnam University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

Biflavonoid; Gene expression; Ginkgetin; Skin inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; BIFLAVONOID; GINKGETIN; INTERLEUKIN 1BETA; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EDEMA; EPIDERMIS HYPERPLASIA; GENE EXPRESSION; HISTOLOGY; MALE; MOUSE; NONHUMAN; SKIN INFLAMMATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIFLAVONOIDS; CHRONIC DISEASE; DERMATITIS; DINOPROSTONE; EDEMA; FLAVONOIDS; GENE EXPRESSION REGULATION; MALE; MICE; MICE, INBRED ICR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN;

EID: 33646446445     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.29.1046     Document Type: Article

References (25)

1. Andersen S., Sjursen W., Laegreid A., Volden G., Johansen B., Inflammation, 18, 1-12 (1994).
2. Fogh K., Kragballe K., Prostag. Other Lipid Mediators, 63, 43-54 (2000).
3. Kampfer H., Brautigan L., Geisslinger G., Pfeilschifter J., Frank J., J. Invest. Dermatol., 120, 880-890 (2003).
4. Lee J. L., Mukhtar H., Bickers D. R., Kopelovich L., Athar M., Toxicol. Appl. Pharmacol., 192, 294-306 (2003).
5. Veale D., Rogers S., Fitzgerald O., Br. J. Dermatol., 132, 32-38 (1995).
6. LaDucca J. R., Caspari A. A., Dermatol. Clin., 19, 617-635 (2001).
7. Bruch-Gerharz D., Fehsel K., Suschek C., Michel G., Ruzicka T., Kolb-Bachofen V., J. Exp. Med., 184, 2007-2012 (1996).
8. Bruch-Gerharz D., Ruzicka T., Kolb-Bachofen V., J. Invest. Dermatol., 110, 1-7 (1998).
9. Amella M., Bronner F., Hagg M., Anton R., Landry Y., Planta Med., 1985, 16-20 (1985).
10. Kim H. P., Mani I., Iversen L., Ziboh V. A., Prostag. Leukot. Essen. Fatty Acids, 58, 17-24 (1998).
11. Selvam C., Jachak M., J. Ethnopharmacol., 95, 209-212 (2004).
12. Banerjee T., Valacchi G., Zibo V. A., van der Vliet A., Mol. Cell Biochem., 238, 105-110 (2002).
13. Baek S. H., Yun S. S., Kwon T. K., Kim J. R., Chang H., Kwak J. Y., Kim J. H., Kwun K. B., Shock, 12, 473-478 (1999).
14. Chang H. W., Baek S. H., Chug K. W., Son K. H., Kim H. P., Kang S. S., Biochem. Biophys. Res. Commun., 205, 843-849 (1994).
15. Kim H. P., Pham H. T., Ziboh V. A., Prostag. Leukot. Essen. Fatty Acids, 65, 281-286 (2001).
16. Kwak W.-J., Han C. K., Son K. H., Chang H. W., Kang S. S., Park B. K., Kim H. P., Planta Med., 68, 316-321 (2002).
17. Kang S. S., Kim J. S., Kwak W.-J., Kim K.-H., Kor. J. Pharmacogn., 21, 111-120 (1990).
18. Stanley P. L., Steiner S., Havens M., Tramposch K. M., Skin Pharmacol., 4, 262-271 (1991).
19. Mitsui G., Mitsui K., Hirano T., Ohara O., Kato M., Niwano Y., Immunol. Lett., 68, 191-197 (2003).
20. Lim H., Park H., Kim H. P., Arch. Pharm. Res., 27, 442-448 (2004).
21. Giannaras A., Selig W., Ellis J., Hullinger T., Eur. J. Pharmacol., 506, 265-271 (2005).
22. Chi Y. S., Lim H., Park H., Kim H. P., Biochem. Pharmacol., 66, 1271-1278 (2003).
23. Gil B., Sanz M. J., Terencio M. C., Gunasegaran R., Paya M., Alcaraz M. J., Biochem. Pharmacol., 53, 733-740 (1997).
24. Hseu Y.-C., Wu F.-Y., Wu J.-J., Chen J.-Y., Chang W.-H., Lu F.-J., Lai Y.-C., Yang H.-L., Int. Immunopharmacol., 5, 1914-1925 (2005).
25. Moolwaney A. S., Igwa O. J., Mol. Brain Res., 137, 202-212 (2005).